Regenerative medicine with marine BMP- activators (MorphoMarin)
ACRONYM
MorphoMarin
Title
Regenerative medicine with marine BMP- activators (MorphoMarin)
General information
Bone Morphogenetic Proteins (BMPs) are endogenous macromolecules (proteins) that are of great importance for bone regeneration due to their ability to stimulate the formation of bone tissue. However, their direct therapeutic use is problematic, so that small molecular BMP stimulators as drug candidates represent urgently needed alternatives.
The MorphoMarin project partners are using a unique technological approach to develop such BMP stimulators: Using an innovative technology platform from the field of "Phenotypic Drug Discovery" (PDD), more than 16,000 extracts of marine (micro)organisms are being tested for BMP activity in high-throughput screening. The chemical space of marine natural products is particularly promising for developing new substances with unique mechanisms of action. Rapid, targeted isolation of these natural products is achieved by combining state-of-the-art computer-aided methods (i.e. metabolomics analyses using machine learning and bioinformatics) with powerful chromatographic and spectroscopic techniques.
The combination of the PDD platform with research into marine natural products opens up promising possibilities and is intended to create a globally unique pharmacological toolbox of BMP stimulators.
The aim of MorphoMarin is to generate a patentable portfolio of early-stage marine development candidates that have a wide range of applications in the pharmaceutical and biotechnology industries. In addition to therapeutic bone regeneration, this also includes broad applications in cell replacement therapy and tissue engineering.
Start
October, 2023
End
September, 2026
Funding (total)
744000
Funding (91探花)
262000
Funding body / Programme
-
BMBF
/
Coordination
Universit盲t Kiel (CAU), Germany
Contact
Partners
Kiel University (CAU), Germany,
